MUMBAI: In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals announced the launch of antiviral drug Favipiravir (brand name FabiFlu) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of…
Tag: Glenmark Pharmaceuticals
Glenmark gets regulator’s approval to try Favipiravir on COVID-19 patients in India
MUMBAI: Glenmark Pharmaceuticals, a research-led pharmaceutical company, announced that it has received approval from the DCGI (Drug Controller General of India), the regulator in India to conduct clinical trials on Favipiravir Antiviral tablets on COVID-19 patients. The product is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm…
Hikma and Glenmark sign agreement to commercialise Ryaltris
LONDON: Hikma Pharmaceuticals and Glenmark Specialty, a Swiss subsidiary of Glenmark Pharmaceuticals, announced the signing of an exclusive US license agreement to commercialise Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR). Under the terms of the agreement, Glenmark will be responsible…
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam
MUMBAI, INDIA: Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux®1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc. According to IQVIATM sales data forthe 12 month period ending July 2019, the Olux®‐E Foam, 0.05%…